

Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke

Submission date 24/10/2008	Recruitment status No longer recruiting	☒ Prospectively registered ☒ Protocol
Registration date 23/01/2009	Overall study status Completed	☒ Statistical analysis plan ☒ Results
Last Edited 29/01/2026	Condition category Circulatory System	☐ Individual participant data

Plain English summary of protocol

Background and study aims

The current guidelines for treating stroke recommend using a drug called clopidogrel or a combination of two drugs called aspirin and dipyridamole for stroke or a transient ischaemic attack (TIA, mini stroke). They are antiplatelet (blood thinning) medications and work by acting on cells in the blood called platelets and reducing the risk of another stroke by making the platelets less 'sticky'. In this study we want to find out if intensive antiplatelet treatment using all three antiplatelet drugs is better than the current guideline treatment in preventing further strokes.

Who can participate?

Adults aged 50 years or over at high risk of recurrent ischaemic stroke.

What does the study involve?

Patients will be randomly allocated to receive either current guideline treatment (clopidogrel alone or combined aspirin and dipyridamole) or to have all three medications (aspirin, dipyridamole and clopidogrel) for 1 month. All other medications will be continued as normal. At the first visit (Day 0) the trial medications are started, questions asked about stroke and medical history, and a medical examination is performed. A small sample of blood will be taken. On Day 7 the trial team will see the patient to see how they are managing with the trial medications. This appointment may be in hospital or at home. A second blood test is also performed. On Day 35 the trial team will see how the patient has recovered from their stroke by doing a neurological examination and also do another blood test. This appointment may be in hospital or at home. On Day 90 patients will complete a questionnaire over the telephone to see how well patients have recovered from their stroke. This involves a short memory test and questions about quality of life and mood. If a telephone call is not possible, a questionnaire will be sent out to the patient in the post.

What are the possible benefits and risks of participating?

The combination of three drugs may reduce the chance of having another stroke soon after the first one. However, this is not guaranteed and there may be no benefit. The information from this study will help in deciding the best treatments for stroke. The main risk is that all three drugs together could cause bleeding. The total amount of time on all three medications will only

be 1 month. The bleeding is usually minor, such as bruising in the skin, but can occasionally be major. In the first part of the study, two patients out of every 100 patients had a major bleeding episode. We expect that the risk will be slightly lower in those patients on guideline treatment and slightly higher in those on intensive antiplatelet treatment. All the antiplatelet drugs used in the TARDIS trial are commonly prescribed in stroke patients and so the side effects are well described. Clopidogrel may cause acid indigestion, diarrhoea or abdominal pains. Dipyridamole may cause headache, dizziness and indigestion. Aspirin may cause indigestion, buzzing or ringing in the ears, stomach ulcers or anaemia. Like all drugs, antiplatelet medications may occasionally cause allergic reactions such as skin rash.

Where is the study run from?

The University of Nottingham (UK)

When is the study starting and how long is it expected to run for?

March 2009 to September 2017

Who is funding the study?

NIHR Health Technology Assessment Programme - HTA (UK)

Who is the main contact?

TARDIS Trial Coordinating Office

tardis@nottingham.ac.uk

Contact information

Type(s)

Scientific

Contact name

Prof Philip Bath

Contact details

Institute of Neuroscience

Stroke, Division of Clinical Neuroscience, School of Medicine

Clinical Sciences Building

City Hospital Campus

Nottingham

United Kingdom

NG5 1PB

+44 (0)115 823 1765

philip.bath@nottingham.ac.uk

Additional identifiers

ClinicalTrials.gov (NCT)

NCT01661322

Clinical Trials Information System (CTIS)

2007-006749-42

Protocol serial number

1.1

Study information

Scientific Title

Safety and efficacy of intensive versus guideline antiplatelet therapy in high-risk patients with recent ischaemic stroke or transient ischaemic attack: a randomised controlled trial

Acronym

TARDIS

Study objectives

To perform a randomised trial assessing the efficacy, safety and tolerability of adding clopidogrel to aspirin and dipyridamole in patients with recent ischaemic stroke or transient ischaemic attack (TIA) and who are at high risk of recurrence. The study will comprise a start-up phase of 350 patients to then expand into a larger trial of 5000 patients assessing the efficacy, safety and health economics of this approach. A secondary hypothesis is that ordinal vascular outcomes will be superior to binary events; the trial is the first to be designed using these outcomes, thus allowing both the frequency and severity of events to be assessed in one measure. Ordinal outcomes include bleeding, adverse events, stroke, myocardial infarction (MI), composite vascular events, and take the form: fatal event/non-fatal severe event/mild event/no event. Conventional binary outcomes will also be measured.

Ethics approval required

Old ethics approval format

Ethics approval(s)

South East MREC approved the protocol (v1.1) on 09/01/2009. Amendments to the protocol (v1.2) were approved on 16/06/2009

Primary study design

Interventional

Study design

Multicentre parallel-group prospective randomized open-label blinded-endpoint controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Ischaemic stroke, transient ischaemic attack (TIA)

Interventions

Current interventions as of 19/06/2014:

Intensive versus guideline antiplatelet therapy will be given for 28 to 30 days along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Randomised patients will receive clopidogrel (loading dose 300 mg, then 75 mg daily), aspirin (loading dose 300 mg, then 50-100 mg daily), and dipyridamole (between 225 and 450 mg daily), or guideline antiplatelet therapy (aspirin and dipyridamole or clopidogrel, doses as above).

Previous interventions:

Aspirin (loading dose 300 mg, then 75 mg daily), clopidogrel (loading dose 300 mg, then 75 mg daily) and dipyridamole (modified release 200 mg twice daily) versus dual antiplatelet therapy (aspirin and dipyridamole, doses as above) randomised 1:1. Dysphagic patients with enteral access will take crushed aspirin (or rectal aspirin), crushed or liquid dipyridamole (75 mg three times daily [tds]), and crushed clopidogrel (if so randomised). Patients having a headache on dipyridamole will have the dose weaned up from daily MR 200 mg or standard release 75 mg once daily [od] to MR 200 mg twice daily [bd]. Fixed-dose combinations of aspirin and dipyridamole can also be used. Open-label clopidogrel will be given for 30 days on top of routine AD (to cover the period of maximum risk of recurrence) and standard 'best care' (including lifestyle advice, BP and lipid lowering). Patients will be recommended to take gastro-prophylaxis against upper gastrointestinal bleeding (proton pump inhibitor/histamine 2 receptor antagonist + H. pylori eradication), as is standard.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Clopidogrel, aspirin, dipyridamole

Primary outcome(s)

Current primary outcome measure as of 25/06/2025:

1. Frequency and severity of recurrent strokes and TIA using information from the follow-up call at Day 90
2. Severity of stroke measured using modified Rankin Scale (mRS) at Baseline and Day 90

Previous primary outcome measure:

The trial will assess ordinal stroke severity at 90 days, assessed as a level ordinal outcome: mRS 6 = fatal-5-4-3-2-1-0-TIA-no stroke; this approach allows for smaller sample sizes than for binary outcomes such as stroke/no stroke. The start-up phase will also assess ordinal bleeding (fatal /major/minor/none) at 35 days (end of treatment) as adjudicated by an independent blinded panel.

Key secondary outcome(s)

Current secondary outcome measures as of 25/06/2025:

1. Headache that required treatment or led to discontinuation, using information from the medical notes at Day 7 and Day 35
2. Recurrent stroke or TIA, using information from the medical notes at Day 7 and Day 35
3. Stroke impairment and neurological deterioration, measured using the National Institutes of Health Stroke Scale (NIHSS) at Baseline, Day 7 and Day 35
4. Composite vascular event, using information from the medical notes and follow-up call at Day 7, Day 35 and Day 90
5. Venous thromboembolism, using information from the medical notes and follow-up call at Day 7, Day 35 and Day 90
6. Haemoglobin, using information from the medical notes at Day 7 and Day 35
7. Bleeding, using information from the medical notes and follow-up call at Day 7, Day 35 and Day 90
8. Myocardial infarction, using information from the medical notes and follow-up call at Day 7,

Day 35 and Day 90

9. SAEs, using information from the medical notes and follow-up call at Day 7, Day 35 and Day 90
10. Headache that required treatment or led to discontinuation, using information from the medical notes at Day 7 and Day 35
11. Length of stay in hospital, using information from the medical notes and at time of discharge letter at discharge/death and follow-up call at Day 90
12. Discharge disposition (death/institution/home), using information from the medical notes and discharge letter at time of discharge/death
13. Ability to perform activities of daily living, measured using the Barthel Index (BI) using information from the medical history at baseline and follow-up call at Day 90
14. Quality of life and health utility score, measured using European Quality of Life-5 Dimensions (EQ-5D) using information from the follow-up call at Day 90
15. Quality of life, measured using the European Quality of Life Visual Analog Scale (EQ-VAS) using information from the follow-up call at Day 90
16. Telephone Mini-Mental State Examination measured using the Montreal Cognitive Assessment (MoCA) using information from the follow-up call at Day 90
17. Telephone Interview Cognition measured using the Montreal Cognitive Assessment (MoCA) Scale - Modified using information from the follow-up call at Day 90
18. Verbal fluency (animal naming over 1 minute) measured using the Montreal Cognitive Assessment (MoCA) using information from medical notes at baseline and the follow-up call at Day 90
19. Mood measured using the Zung Depression Scale (ZDS) using information from the follow-up call at Day 90

Previous secondary outcome measures:

1. Secondary outcomes at 35 and 90 days:
 - 1.1. Binary stroke
 - 1.2. Ordinal stroke (fatal stroke/non-fatal stroke/no stroke)
 - 1.3. Binary myocardial infarction
 - 1.4. Ordinal myocardial infarction (fatal MI/non-fatal MI/no MI)
 - 1.5. Binary composite vascular outcome (non-fatal MI and stroke, vascular death)
 - 1.6. Ordinal composite vascular outcome
 - 1.7. Composite stroke, TIA, acute coronary syndromes and all-cause death
2. Secondary outcomes at 90 days:
 - 2.1. Function (modified Rankin Scale [mRS], Barthel Index)
 - 2.2. Cognition (Telephone Interview for Cognitive Status [TICS]/animal naming)
 - 2.3. Quality of life (EuroQoL/EQ-5D instrument)
 - 2.4. Mood (Zung)
 - 2.5. Disposition (home, institution, dead)
 - 2.6. Days at home
 - 2.7. Economic activity
3. Tolerability: Proportion of patients completing 28 days of randomised treatment
4. Feasibility: Recruitment rate per week
5. Safety measures at 35 and 90 days:
 - 5.1. Death
 - 5.2. Binary major bleeding (fatal, symptomatic, causing a fall in haemoglobin of greater than 2 g /l, or leading to transfusion of greater than 2 units of blood/red cells)
 - 5.3. Binary minor bleeding (e.g. bruising)
 - 5.4. Binary all bleeding
 - 5.5. Symptomatic intracerebral haemorrhage
 - 5.6. Major extracranial bleeding
 - 5.7. Binary serious adverse events

- 5.8. Ordinal adverse events (fatal/serious/other/none)
- 5.9. Full blood count (at 35 days)
- 5.10. Thrombotic thrombocytopenic purpura
- 5.11. Granulocytopenia

Data from two substudies will power substudies within the future main trial:

- 1. Transcranial Doppler: TCD recordings will be performed from the middle cerebral artery (MCA) at baseline and day 3 $\pm$ 1
- 2. Platelet function: platelet expression of P-selectin will be used to monitor platelet effects in patients. Blood will be taken from all patients at baseline and day 7 $\pm$ 1

Completion date

30/09/2017

Eligibility

Key inclusion criteria

Current inclusion criteria as of 25/06/2025:

- 1. Age $\geq$ 50 years
- 2. Event to randomization $\leq$ 48 h (24–48 h if thrombolysed)
- 3. Index event is a TIA with:
 - 3.1. Resolved limb weakness and/or dysphasia
 - 3.2. Duration 10 min to 24 h after onset (i.e. resolution between 24 h and randomization)
 - 3.3. ABCD2 score $\geq$ 4; AND/OR crescendo TIA; AND/OR already on dual antiplatelet therapy
- 4. Index event is a non-cardioembolic ischemic stroke with:
 - 4.1. Ongoing limb weakness OR ongoing facial weakness with resolved limb weakness; AND/OR dysphasia; AND/OR ongoing isolated hemianopia (with positive neuroimaging evidence showing ischemic stroke in occipital lobe); AND duration $\geq$ 1 hour
 - 4.2. Resolved limb weakness; AND/OR dysphasia; AND duration >24 h after onset (i.e. resolution between 24 h and randomization)
- 5. Willing and able to provide written informed consent; proxy consent is acceptable if patients are dysphasic or confused, in accordance with the practice of the local site

Previous inclusion criteria from 19/06/2014 to 25/06/2025:

Adults at high risk of recurrent ischaemic stroke:

- 1. Age $\geq$ 50 years
- 2. Within 48 hours of ictus (24-48 hours if thrombolysed)
- 3. TIA with limb weakness and/or dysphasia lasting between 10 minutes and <24 hours with no residual symptoms and presenting with any of the following:
 - 3.1. ABCD2 score >4
 - 3.2. Crescendo TIA
 - 3.3. Already on dual antiplatelet therapy with aspirin and dipyridamole
 - 3.4. Positive neuroimaging evidence to support the new event, ischaemic stroke on MR diffusion imaging

Notes:

- 1. Patients who are on monotherapy e.g. aspirin alone, or clopidogrel alone, or dipyridamole alone, are eligible for recruitment. Similarly, patients who are on combined therapy aspirin + dipyridamole, are eligible for recruitment if they fulfil the above criteria.
- 2. Patients with posterior fossa events are eligible if they fulfil the above criteria.
- 3. Neuroimaging is not necessary for transient ischaemic attack. Crescendo TIA is >1 TIA in 1

week and the onset time of last TIA is taken as time of ictus.

4. Ischaemic non-cardioembolic stroke presenting with any of the following:

- 4.1. Ongoing limb weakness of more than 1 hour duration; and/or
- 4.2. Ongoing dysphasia of more than 1 hour duration; and/or
- 4.3. Resolved limb weakness of more than 1 hour duration with ongoing facial weakness; and/or
- 4.4. Ongoing isolated hemianopia of more than 1 hour duration with positive neuroimaging evidence to support the new event (e.g. ischaemic stroke in the occipital lobe) and/or
- 4.5. Limb weakness that resolves between 24-48 hours after onset; and/or
- 4.6. Dysphasia that resolves between 24-48 hours after onset; and/or
- 4.7. Positive neuroimaging to support the new ischaemic event with MR diffusion.
- 4.8. Already on combined dual antiplatelet therapy (aspirin + dipyridamole)

Neuroimaging is essential for ischaemic stroke to exclude intracranial haemorrhage and a non-stroke diagnosis. If the patient received thrombolysis, a post-thrombolysis/pre-TARDIS scan needs to be done to exclude new thrombolysis-associated bleeding prior to enrolment.

Typically, this is done routinely as 'standard of care', but if it is not done, then it must be done prior to enrolment.

5. Patients thrombolysed for stroke with full recovery in less than 24 hours from the onset of symptoms are eligible for inclusion providing neuroimaging post-thrombolysis excludes intracranial haemorrhage.

6. Informed consent from the participant. If the participant is unable to give meaningful consent, e.g. due to dysphasia, confusion, or reduced conscious level, proxy consent may be obtained from a relative, carer or legal representative.

Inclusion criteria from 25/03/2010 to 19/06/2014:

Adults at high risk of recurrent ischaemic stroke:

1. Acute non-cardioembolic ischaemic stroke (<48 hours of onset). All strokes must have motor weakness or dysphasia at the time of randomisation.
2. Acute TIA (<48 hours of onset) with one or more of: crescendo TIA (>1 TIA within 1 week), and/or admitted on dual antiplatelet therapy (aspirin/dipyridamole, aspirin/clopidogrel, clopidogrel/dipyridamole), and/or with an ABCD2 score >4. All TIAs must have motor weakness and/or dysphasia lasting at least 10 minutes
3. Meaningful consent, or consent from a relative, carer or legal representative if the patient is unable to give meaningful consent (e.g. in cases of dysphasia, confusion, or reduced conscious level)

Inclusion criteria at time of registration:

Adults of either sex at high risk of recurrent ischaemic stroke:

1. Acute non-cardioembolic ischaemic stroke (less than 48 hours of onset)
2. Acute TIA (less than 48 hours of onset) with one or more of: crescendo TIA (greater than one TIA within 1 week), and/or admitted on dual antiplatelet therapy (aspirin/dipyridamole, aspirin/clopidogrel, clopidogrel/dipyridamole), and/or with an ABCD2 score greater than 5 (stroke rate at 13 weeks greater than 10%)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

50 Years

Upper age limit

110 Years

Sex

All

Total final enrolment

0

Key exclusion criteria

Current exclusion criteria as of 25/06/2025:

1. Isolated sensory symptoms, facial weakness, or vertigo/dizziness
2. Isolated hemianopia without positive neuroimaging evidence
3. Intracranial haemorrhage
4. Baseline neuroimaging shows intracranial haemorrhage or parenchymal haemorrhagic transformation (PH 1 or 2) of infarct, subarachnoid haemorrhage, or other non-ischemic cause for symptoms
5. Presumed cardioembolic stroke (e.g. history of current atrial fibrillation (AF), myocardial infarction <3 months)
6. Contraindications to, or intolerance of, aspirin, clopidogrel, or dipyridamole
7. Definite need for aspirin, clopidogrel, or dipyridamole individually or in combination (e.g. aspirin and clopidogrel for recent myocardial infarction (MI)/acute coronary syndrome)
8. Definite need for full dose oral (e.g. apixaban, dabigatran, rivaroxaban, warfarin) or medium to high dose parenteral (e.g. heparin) anticoagulation
9. Definite need for glycoprotein IIb/IIIa inhibitor
10. No enteral access
11. Pre-morbid dependency (modified Rankin Scale [mRS] >2)
12. Severe high BP (BP >185/110 mmHg)
13. Haemoglobin <100 g/L
14. Platelet count <100 x 10⁹/L or >600 x 10⁹/L
15. White cell count <3.5 x 10⁹/L or >30 x 10⁹/L
16. Major bleeding within 1 year (e.g. peptic ulcer, intracerebral haemorrhage)
17. Planned surgery in next 3 months (e.g. known need for carotid endarterectomy)
18. Concomitant acute coronary syndrome (e.g. ST segment elevation myocardial infarction [STEMI] or non-STEMI [NSTEMI])
19. Stroke secondary to a procedure (e.g. carotid or coronary intervention)
20. Coma (Glasgow Coma Scale [GCS] <8)
21. Non-stroke life expectancy <6 months
22. Known dementia
23. Women of childbearing potential, pregnant, or breastfeeding
24. Geographical or other factors that may interfere with follow-up
25. Patients who have not had post-thrombolysis neuroimaging
26. Patients may be enrolled concurrently into observational studies or non-drug/device trials

Previous exclusion criteria from 19/06/2014 to 25/06/2025:

1. Age <50 years
2. Isolated sensory symptoms or vertigo/dizziness or facial weakness
3. Isolated hemianopia without positive neuroimaging evidence

4. Intracranial haemorrhage
5. Baseline neuroimaging showing parenchymal haemorrhagic transformation (PH I/II) of infarct, subarachnoid haemorrhage or other non-ischaemic cause for symptoms
6. Presumed cardioembolic stroke (e.g. history or current AF, myocardial infarction within 3 months)
7. Participants with contraindications to, or intolerance of, aspirin, clopidogrel or dipyridamole.
8. Participants with definite need for treatment with aspirin, clopidogrel or dipyridamole individually or in combination (e.g. aspirin and clopidogrel for recent MI/acute coronary syndrome)
9. Definite need for full-dose oral (e.g. warfarin, dabigatran) or medium to high-dose parenteral (e.g. heparin) anti-coagulation. NB Low-dose heparin for DVT prophylaxis is allowed
10. Definite need for glycoprotein IIb-IIIa inhibitors
11. Patients who have received thrombolysis within 24 hours
12. No enteral access
13. Pre-morbid dependency (mRS >2)
14. Severe high BP (BP >185/110 mmHg)
15. Haemoglobin less than 10 g/dL
16. Platelet count more than $600 \times 10^9 /L$ or less than $100 \times 10^9 /L$
17. White cell count more than $30 \times 10^9 /L$ or less than $3.5 \times 10^9 /L$
18. Major bleeding within 1 year (e.g. peptic ulcer, intracerebral haemorrhage)
19. Planned surgery during 3-month follow-up (e.g. carotid endarterectomy)
20. Concomitant STEMI or NSTEMI.
21. Stroke secondary to a procedure (e.g. carotid or coronary intervention)
22. Coma (GCS<8)
23. Non-stroke life expectancy <6 months
24. Dementia
25. Participation in another drug or device trial concurrently or within 30 days (participants may take part in observational studies or non-drug or devices trials)
26. Geographical or other factors that may interfere with follow-up, e.g. no fixed address or telephone contact number, not registered with a GP, or overseas visitor.
27. Females of childbearing potential, pregnancy or breastfeeding
28. Patients who have not had post-thrombolysis neuroimaging.
29. Patients on aspirin and clopidogrel prior to the underlying event.

Previous exclusion criteria from 25/03/2010 to 19/06/2014:

1. Age <50 years
2. Motor weakness or dysphasia lasting <10 minutes
3. Pure sensory, vertigo or dizziness, speech or visual disturbance symptoms without weakness or dysphasia
4. Patients with contraindications to, or intolerance of, aspirin, clopidogrel or dipyridamole
5. Patients with a definite need for treatment with clopidogrel (e.g. recent MI)
6. Pre-morbid dependency (mRS>2)
7. No enteral access
8. Parenchymal haemorrhagic transformation (PH I/II), subarachnoid haemorrhage or other non-ischaemic cause for weakness
9. TIA not fulfilling inclusion criteria
10. Definite need for full dose oral (e.g. warfarin) or parental (e.g. heparin or glycoprotein IIb IIIa inhibitors) anti-coagulation. NB Low-dose heparin for DVT prophylaxis is allowed.
11. Received thrombolysis within the last 30 hours
12. Presumed cardioembolic stroke (e.g. AF, recent MI, or other conditions need for anticoagulation)
13. Severe high BP (BP>185/110 mmHg)

14. Known haemoglobin less than 10 g/dL
15. Known platelet count less than $100 \times 10^9 /L$
16. Known white cell count less than $3.5 \times 10^9 /L$
17. Bleeding within 1 year (e.g. peptic ulcer, intracerebral haemorrhage)
18. Planned surgery during 3-month follow-up (e.g. carotid endarterectomy)
19. Concomitant acute coronary syndrome
20. Stroke secondary to a procedure (e.g. carotid or coronary intervention)
21. Coma (GCS<8)
22. Non-stroke life expectancy <6 months
23. Dementia
24. Participation in another drug trial concurrently or within 30 days (Patients may be randomised into observational studies or non-drug trials)
25. Not available for follow-up, e.g. no fixed address, overseas visitor
26. Females of childbearing potential, pregnancy or breastfeeding

Note: Clopidogrel will be stopped around procedures that become necessary after enrolment

Previous exclusion criteria at time of registration:

1. Aged less than 40 years
2. Motor weakness lasting less than 30 minutes (pure sensory, vertigo or dizziness, speech or visual disturbance symptoms without weakness are excluded)
3. Patients with contraindications to, or intolerance of, aspirin, clopidogrel or dipyridamole
4. Pre-morbid dependency (modified Rankin Scale [mRS] greater than 3)
5. No enteral access
6. Parenchymal haemorrhagic transformation (PH I/II), subarachnoid haemorrhage or other non-ischaeemic cause for weakness
7. TIA not fulfilling inclusion criteria
8. Definite need for, or currently on triple antiplatelet therapy or anticoagulation
9. Indication for, or received (in the last week), thrombolysis
10. Presumed cardioembolic stroke (e.g. atrial fibrillation [AF], recent MI, or other conditions need for anticoagulation)
11. Severe high blood pressure (BP) (greater than 185/110 mmHg)
12. Bleeding within 1 year (e.g. peptic ulcer, intracerebral haemorrhage)
13. Planned surgery during 3-month follow-up (e.g. carotid endarterectomy)
14. Concomitant acute coronary syndrome
15. Stroke secondary to a procedure (e.g. carotid or coronary intervention)
16. Planned surgery during the first month post stroke (e.g. carotid endarterectomy)
17. Coma (Glasgow Coma Scale [GCS] less than 8)
18. Non-stroke life expectancy less than 6 months
19. Dementia
20. Participation in another drug trial concurrently or within 30 days (patients may be randomised into observational studies or non-drug trials)
21. Not available for follow-up, e.g. no fixed address, overseas visitor
22. Females of childbearing potential, pregnancy or breastfeeding

Note: Clopidogrel will be stopped around procedures that become necessary after enrolment

Date of first enrolment

01/03/2009

Date of final enrolment

30/09/2017

Locations

Countries of recruitment

United Kingdom

England

Denmark

Georgia

New Zealand

Study participating centre

Institute of Neuroscience

-

Nottingham

England

NG5 1PB

Sponsor information

Organisation

University of Nottingham (UK)

ROR

<https://ror.org/01ee9ar58>

Funder(s)

Funder type

Charity

Funder Name

British Heart Foundation (BHF) (UK)

Alternative Name(s)

The British Heart Foundation, the_bhf, BHF

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Funder Name

Health Technology Assessment Programme

Alternative Name(s)

NIHR Health Technology Assessment Programme, Health Technology Assessment (HTA), HTA

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	03/03/2018		Yes	No
Results article	results	01/08/2018		Yes	No
Results article		30/07/2023	21/07/2023	Yes	No
Results article	Re-Assessment of the TARDIS trial	05/07/2023	25/09/2023	Yes	No
Results article	A secondary analysis of the TARDIS trial of antiplatelet groups assessing the treatment effect of triple vs. guideline antiplatelet therapy within this pre-specified subgroup	24/01/2026	29/01/2026	Yes	No
Protocol article	protocol	01/10/2015		Yes	No

Basic results			10/09/2019	No	No
Statistical Analysis Plan	statistical analysis plan		01/04/2015	No	No
Study website	Study website		11/11/2025	11/11/2025	No Yes